GlassScriptPhysician profile
Nicholas Zendler
NPI 1275897068
$1,030.32
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $163 · 2021: $140 · 2023: $154 · 2024: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $295.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $183.50 | 2019-2021 | |
| Greenwich Biosciences, INC. | $173.72 | 2019-2020 | |
| Livanova USA, INC. | $170.52 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Jazz Pharmaceuticals INC. | $122.85 | 2023 | |
| Sunovion Pharmaceuticals INC. | $103.03 | 2019-2021 | |
| Amgen INC. | $82.59 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $54.55 | 2019-2021 | |
| Sk Life Science, INC. | $43.09 | 2021 | |
| Neurelis, INC. | $31.49 | 2023 | Valtoco |
| Upsher-Smith Laboratories LLC | $23.39 | 2019 | |
| Lundbeck LLC | $21.52 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Zendler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.